IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In Re the Application of: |) Group Art Unit: 1648 |
|--|---|
| COX |) Examiner: Lucas, Z. |
| Serial No.: Not Yet Assigned |) INFORMATION DISCLOSURE) STATEMENT |
| Filed: February 5, 2004 |) <u>STATEMENT</u>) |
| Atty. File No.: 4152-1-PUS-7 |) EXPRESS MAIL: EL975241384US |
| For: "CYSTEINE VARIANTS OF INTERLEUKIN-11" |))) |
| Commissioner for Patents | |

P.O. Box 1450 Alexandria VA 22313-1450

Dear Sir:

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby submits the enclosed PTO Form 1449. The documents identified herein were of record in U.S. Patent Application Serial No. 10,400,377, and since the above-identified patent application is a continuation thereof, copies of the identified documents are not being submitted under 37 CFR § 1.98(d). Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By:

Angela Dallas Sebor Registration No. 42,460 1560 Broadway, Suite 1200 Denver, CO 80202-5141

(303) 863-9700

Date: Flbruary 5, 2004

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

| ATTY. DOCKET NO. 4152-1-PUS-7 | SERIAL NO. Not Yet Assigned | |
|----------------------------------|--------------------------------|--|
| APPLICANT COX | | |
| FILING DATE February 5, 2004 | GROUP ART | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROP. |
|----------------------|---|--------------------|----------|-------------------|-------|--------------|---------------------------|
| | 1 | 4,588,585 | 5/13/86 | Mark et al. | 424 | 85 | |
| | 2 | 5,166,322 | 11/24/92 | Shaw et al. | 530 | 351 | 200 2 |
| | 3 | 5,206,344 | 4/27/93 | Katre et al. | 530 | 351 | |
| | 4 | 5,208,158 | 5/4/93 | Bech et al. | 435 | 219 | |
| | 5 | 5,766,897 | 6/16/98 | Braxton | 435 | 172.1 | |
| | 6 | 5,849,535 | 12/1998 | Cunningham et al. | 435 | 243 | |

FOREIGN PATENT DOCUMENTS

| | | | | | SUB CLASS | TRANSLATION | |
|----|--------------------|---------|---------|-------|--------------|-------------|----|
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | | YES | NO |
| 7 | 0 458 064 A2 | 11/1991 | Europe | | | | |
| 8 | WO 93/00109 | 7/1993 | PCT | | _ | | |
| 9 | WO 95/11987 | 4/1995 | PCT | | | | |
| 10 | WO 96/31537 | 10/1996 | PCT | | | | |
| 11 | WO 95/32003 | 11/1995 | PCT | | | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

| 12 | Bazan, Immunology Today, 11:350-354 (1990) |
|----|--|
| 13 | Campbell et al., J. Peptide Res., 49:527-537 (1997) |
| 14 | Cunningham et al., Science, 243:1330-1336 (1989) |
| 15 | Goodson and Katre, Bio/Technology, 8:343-346 (1990) |
| 16 | Karpusas et al., <i>Proc. Natl. Acad. Sci. USA</i> , 94 :11813-11818 (1997) |
| 17 | Lowman and Wells, J. Mol. Biol., 234:564-578 (1993) |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
| | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

| ATTY. DOCKET NO. 4152-1-PUS-7 | SERIAL NO. Not Yet Assigned |
|----------------------------------|--------------------------------|
| APPLICANT COX | |
| FILING DATE February 5, 2004 | GROUP ART |

| 18 | 18 Mott and Compbell, Curr Opin Struct Biol, 5:114-121 (1995) | |
|---|---|--|
| 19 | Sprang and Bazan, Curr. Op. Struct. Biol., 3:815-827 (1993) | |
| 20 | Wells, Ann. Rev. Biochem., 65:609-634 (1996). | |
| 21 Zalipsky, S., Adv. Drug Delivery Rev., 16:157-182 (1995) | | |

EXAMINER

DATE CONSIDERED